DataMEDS AI Secures Exclusive U.S. Rights to REBOOT Health AI's GLP-1 Weight Management Platform

DataMEDS AI and REBOOT Health AI Form Strategic Partnership

DataMEDS AI, Inc. (NASDAQ:MEDS) has entered into an exclusive license, revenue sharing and marketing agreement with REBOOT Health AI, Inc. for Direct-To-Consumer GLP-1 weight management platform rights in the United States1

1

2

2

. The Tampa-based healthcare company will integrate REBOOT's proprietary care management platform into its recently launched Health Lives Here mobile application, creating a comprehensive solution for patients taking GLP-1 receptor agonist medications. REBOOT Health AI operates as a subsidiary of Data Health Partners, Inc., bringing its data-driven, evidence-based outcome optimization technology to this strategic partnership1

1

.

Revenue Sharing Model and Platform Integration

Under the terms of the agreement, DataMEDS AI will share revenue generated from subscription-based services related to the GLP Management Platform's use within the Health Lives Here app2

2

. The company plans to develop GLP-1 medication management support modules offered on a monthly subscription basis, available for download on both Android and iOS devices1

1

. Gerald E. Commissiong, Interim Co-CEO of DataMEDS AI, stated the agreement provides access to key intellectual property and a weight care management platform that enables Health Lives Here to position itself in emerging competition to acquire and retain consumers seeking successful outcomes while on GLP-1 medications2

2

.

Intellectual Property Portfolio and Legal Landscape

REBOOT's patent family includes six patents and six patent pending applications related to optimizing data-driven outcomes, goal progression tracking, and AI-enhanced chronic disease management1

1

2

2

. Data Health Partners, REBOOT's parent company, is currently in litigation with Teladoc Health regarding this intellectual property portfolio in the case Data Health Partners, Inc. v. Teladoc Health, Inc.1

1

. This ongoing legal matter highlights the competitive value of the technology DataMEDS AI has now licensed for exclusive use in the Direct-To-Consumer GLP-1 weight management space.

Health Lives Here App Features and Ecosystem

The Health Lives Here mobile app is designed to consolidate electronic health records data for patients and integrate wearables data while producing a streamlined health dashboard for tracking goals and progress1

1

2

2

. The platform will provide access to products including Forzet™, a proprietary medical food for dietary management of muscle loss associated with weight loss therapies1

1

. Paul Arena, Chief Executive Officer of REBOOT, noted that DataMEDS' partnership with NFL Alumni Health provides a marketing platform to attract customers to the Health Lives Here app1

1

.

Vertically Integrated Business Model and Market Positioning

DataMEDS AI expects the subscription-based services to drive revenue associated with pharmacy dispensing, nutraceutical sales, diagnostic lab testing and physician services as part of its vertically integrated business model1

1

. The company's Corexa Health pharmacy and distribution divisions are licensed to dispense and distribute FDA-approved GLP-1 receptor agonist drugs, while patients and providers using the Health Lives Here mobile application can choose their own pharmacy1

1

2

2

. Tollo Health, a nutraceutical partner led by Interim Co-CEO Gerald Commissiong, manufactures medical foods and dietary supplements and intends to build targeted nutritional support programs for patients on GLP-1 receptor agonist drugs2

2

. This AI-driven healthcare solution aims to help customers meet their goals while optimizing to minimize side effects through behavior modification and nutraceutical products1

1

.